214 related articles for article (PubMed ID: 24827725)
1. Mmp-9 responsive PEG cleavable nanovesicles for efficient delivery of chemotherapeutics to pancreatic cancer.
Kulkarni PS; Haldar MK; Nahire RR; Katti P; Ambre AH; Muhonen WW; Shabb JB; Padi SK; Singh RK; Borowicz PP; Shrivastava DK; Katti KS; Reindl K; Guo B; Mallik S
Mol Pharm; 2014 Jul; 11(7):2390-9. PubMed ID: 24827725
[TBL] [Abstract][Full Text] [Related]
2. pH-Sensitive Nanodrug Carriers for Codelivery of ERK Inhibitor and Gemcitabine Enhance the Inhibition of Tumor Growth in Pancreatic Cancer.
Ray P; Dutta D; Haque I; Nair G; Mohammed J; Parmer M; Kale N; Orr M; Jain P; Banerjee S; Reindl KM; Mallik S; Kambhampati S; Banerjee SK; Quadir M
Mol Pharm; 2021 Jan; 18(1):87-100. PubMed ID: 33231464
[TBL] [Abstract][Full Text] [Related]
3. PEG-b-poly (carbonate)-derived nanocarrier platform with pH-responsive properties for pancreatic cancer combination therapy.
Ray P; Confeld M; Borowicz P; Wang T; Mallik S; Quadir M
Colloids Surf B Biointerfaces; 2019 Feb; 174():126-135. PubMed ID: 30447521
[TBL] [Abstract][Full Text] [Related]
4. Effective encapsulation and biological activity of phosphorylated chemotherapeutics in calcium phosphosilicate nanoparticles for the treatment of pancreatic cancer.
Loc WS; Linton SS; Wilczynski ZR; Matters GL; McGovern CO; Abraham T; Fox T; Gigliotti CM; Tang X; Tabakovic A; Martin JA; Clawson GA; Smith JP; Butler PJ; Kester M; Adair JH
Nanomedicine; 2017 Oct; 13(7):2313-2324. PubMed ID: 28673852
[TBL] [Abstract][Full Text] [Related]
5. Matrix metalloproteinase-9 (MMP-9) as an activator of nanosystems for targeted drug delivery in pancreatic cancer.
Grünwald B; Vandooren J; Locatelli E; Fiten P; Opdenakker G; Proost P; Krüger A; Lellouche JP; Israel LL; Shenkman L; Comes Franchini M
J Control Release; 2016 Oct; 239():39-48. PubMed ID: 27545397
[TBL] [Abstract][Full Text] [Related]
6. Effective targeting of gemcitabine to pancreatic cancer through PEG-cored Flt-1 antibody-conjugated dendrimers.
Öztürk K; Esendağlı G; Gürbüz MU; Tülü M; Çalış S
Int J Pharm; 2017 Jan; 517(1-2):157-167. PubMed ID: 27965135
[TBL] [Abstract][Full Text] [Related]
7. Enhancement of Pancreatic Cancer Therapy Efficacy by Type-1 Matrix Metalloproteinase-Functionalized Nanoparticles for the Selective Delivery of Gemcitabine and Erlotinib.
Yin N; Yu H; Zhang X; Lv X
Drug Des Devel Ther; 2020; 14():4465-4475. PubMed ID: 33122890
[TBL] [Abstract][Full Text] [Related]
8. Use of a lipid-coated mesoporous silica nanoparticle platform for synergistic gemcitabine and paclitaxel delivery to human pancreatic cancer in mice.
Meng H; Wang M; Liu H; Liu X; Situ A; Wu B; Ji Z; Chang CH; Nel AE
ACS Nano; 2015; 9(4):3540-57. PubMed ID: 25776964
[TBL] [Abstract][Full Text] [Related]
9. Dual Enzymatic Reaction-Assisted Gemcitabine Delivery Systems for Programmed Pancreatic Cancer Therapy.
Han H; Valdepérez D; Jin Q; Yang B; Li Z; Wu Y; Pelaz B; Parak WJ; Ji J
ACS Nano; 2017 Feb; 11(2):1281-1291. PubMed ID: 28071891
[TBL] [Abstract][Full Text] [Related]
10. Tissue-Penetrating, Hypoxia-Responsive Echogenic Polymersomes For Drug Delivery To Solid Tumors.
Kulkarni P; Haldar MK; Karandish F; Confeld M; Hossain R; Borowicz P; Gange K; Xia L; Sarkar K; Mallik S
Chemistry; 2018 Aug; 24(48):12490-12494. PubMed ID: 29968262
[TBL] [Abstract][Full Text] [Related]
11. Three-dimensional collagen I promotes gemcitabine resistance in pancreatic cancer through MT1-MMP-mediated expression of HMGA2.
Dangi-Garimella S; Krantz SB; Barron MR; Shields MA; Heiferman MJ; Grippo PJ; Bentrem DJ; Munshi HG
Cancer Res; 2011 Feb; 71(3):1019-28. PubMed ID: 21148071
[TBL] [Abstract][Full Text] [Related]
12. Targeting Pancreatic Cancer Cells and Stellate Cells Using Designer Nanotherapeutics in vitro.
Elechalawar CK; Hossen MN; Shankarappa P; Peer CJ; Figg WD; Robertson JD; Bhattacharya R; Mukherjee P
Int J Nanomedicine; 2020; 15():991-1003. PubMed ID: 32103952
[TBL] [Abstract][Full Text] [Related]
13. Self-Assembled Gemcitabine Prodrug Nanoparticles Show Enhanced Efficacy against Patient-Derived Pancreatic Ductal Adenocarcinoma.
Wu L; Zhang F; Chen X; Wan J; Wang Y; Li T; Wang H
ACS Appl Mater Interfaces; 2020 Jan; 12(3):3327-3340. PubMed ID: 31872760
[TBL] [Abstract][Full Text] [Related]
14. EGFR-targeted gelatin nanoparticles for systemic administration of gemcitabine in an orthotopic pancreatic cancer model.
Singh A; Xu J; Mattheolabakis G; Amiji M
Nanomedicine; 2016 Apr; 12(3):589-600. PubMed ID: 26656632
[TBL] [Abstract][Full Text] [Related]
15. Preparation, physicochemical characterization and cytotoxicity in vitro of gemcitabine-loaded PEG-PDLLA nanovesicles.
Jia L; Zheng JJ; Jiang SM; Huang KH
World J Gastroenterol; 2010 Feb; 16(8):1008-13. PubMed ID: 20180242
[TBL] [Abstract][Full Text] [Related]
16. Biodegradable, pH-Sensitive Hollow Mesoporous Organosilica Nanoparticle (HMON) with Controlled Release of Pirfenidone and Ultrasound-Target-Microbubble-Destruction (UTMD) for Pancreatic Cancer Treatment.
Gao F; Wu J; Niu S; Sun T; Li F; Bai Y; Jin L; Lin L; Shi Q; Zhu LM; Du L
Theranostics; 2019; 9(20):6002-6018. PubMed ID: 31534533
[TBL] [Abstract][Full Text] [Related]
17. Phospho-valproic acid inhibits pancreatic cancer growth in mice: enhanced efficacy by its formulation in poly-(L)-lactic acid-poly(ethylene glycol) nanoparticles.
Mattheolabakis G; Wang R; Rigas B; Mackenzie GG
Int J Oncol; 2017 Oct; 51(4):1035-1044. PubMed ID: 28849098
[TBL] [Abstract][Full Text] [Related]
18. Metformin-Induced Stromal Depletion to Enhance the Penetration of Gemcitabine-Loaded Magnetic Nanoparticles for Pancreatic Cancer Targeted Therapy.
Han H; Hou Y; Chen X; Zhang P; Kang M; Jin Q; Ji J; Gao M
J Am Chem Soc; 2020 Mar; 142(10):4944-4954. PubMed ID: 32069041
[TBL] [Abstract][Full Text] [Related]
19. Two-wave nanotherapy to target the stroma and optimize gemcitabine delivery to a human pancreatic cancer model in mice.
Meng H; Zhao Y; Dong J; Xue M; Lin YS; Ji Z; Mai WX; Zhang H; Chang CH; Brinker CJ; Zink JI; Nel AE
ACS Nano; 2013 Nov; 7(11):10048-65. PubMed ID: 24143858
[TBL] [Abstract][Full Text] [Related]
20. Designing Liposomes To Suppress Extracellular Matrix Expression To Enhance Drug Penetration and Pancreatic Tumor Therapy.
Ji T; Lang J; Wang J; Cai R; Zhang Y; Qi F; Zhang L; Zhao X; Wu W; Hao J; Qin Z; Zhao Y; Nie G
ACS Nano; 2017 Sep; 11(9):8668-8678. PubMed ID: 28806504
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
